ChiCTR2400092120 版本V1.0 版本创建时间2024/11/11 10:53:14 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400092120 

最近更新日期:

Date of Last Refreshed on:

2024-11-11 10:53:00 

注册时间:

Date of Registration:

2024-11-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

人工智能在超声诊断子宫及卵巢疾病中的应用

Public title:

Application of artificial intelligence in ultrasound diagnosis of uterine and ovarian diseases

注册题目简写:

English Acronym:

研究课题的正式科学名称:

人工智能在超声诊断子宫及卵巢疾病中的应用

Scientific title:

Application of artificial intelligence in ultrasound diagnosis of uterine and ovarian diseases

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张皓楠 

研究负责人:

周怡 

Applicant:

Haonan Zhang 

Study leader:

Yi Zhou 

申请注册联系人电话:

Applicant telephone:

+86 189 5515 8427

研究负责人电话:

Study leader's
telephone:

+86 157 1551 1277

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

18955158427@163.com

研究负责人电子邮件:

Study leader's E-mail:

xiaodouziaimeili@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

安徽省合肥市蜀山区绩溪路218号

研究负责人通讯地址:

安徽省合肥市蜀山区绩溪路218号

Applicant address:

No.218 Jixi Road, Shushan District, Hefei City, Anhui Province

Study leader's address:

No.218 Jixi Road, Shushan District, Hefei City, Anhui Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

安徽医科大学第一附属医院

Applicant's institution:

The First Affiliated Hospital of Anhui Medical University

研究负责人所在单位:

安徽医科大学第一附属医院

Affiliation of the Leader:

The First Affiliated Hospital of Anhui Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

安医一附院论审-PJ2024-09-52

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

安徽医科大学第一附属医院临床医学研究伦理委员会

Name of the ethic committee:

Clinical Research Ethics Committee of the First Affiliated Hospital of Anhui Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-10-01 00:00:00

伦理委员会联系人:

陈奕豪

Contact Name of the ethic committee:

Yihao Chen

伦理委员会联系地址:

安徽省合肥市蜀山区绩溪路218号

Contact Address of the ethic committee:

No.218 Jixi Road, Shushan District, Hefei City, Anhui Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 551 6292 3102

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

安徽医科大学第一附属医院

Primary sponsor:

the First Affiliated Hospital of Anhui Medical University

研究实施负责(组长)单位地址:

安徽省合肥市蜀山区绩溪路218号

Primary sponsor's address:

No.218 Jixi Road, Shushan District, Hefei City, Anhui Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽省

市(区县):

合肥市

Country:

China

Province:

Anhui

City:

Hefei

单位(医院):

安徽医科大学第一附属医院

具体地址:

安徽省合肥市蜀山区绩溪路218号

Institution
hospital:

the First Affiliated Hospital of Anhui Medical University

Address:

No.218 Jixi Road, Shushan District, Hefei City, Anhui Province

经费或物资来源:

安徽医科大学第一附属医院

Source(s) of funding:

the First Affiliated Hospital of Anhui Medical University

研究疾病:

子宫及卵巢疾病  

Target disease:

Diseases of the uterus and ovaries

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

通过超声对正常及异常情况的获取,探讨基于人工智能在超声诊断妇科子宫卵巢疾病中的应用。  

Objectives of Study:

Through the acquisition of normal and abnormal conditions by ultrasound, the application of artificial intelligence in the diagnosis of gynecological uterine and ovarian diseases by ultrasound was discussed.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1)妇科常见病:子宫肌瘤、子宫肉瘤、子宫内膜癌、妊娠滋养细胞疾病、宫颈癌、卵巢良恶性肿瘤、子宫内膜异位症等常见妇科疾病。 2)年龄20-80岁 3)能在我院有手术或者穿刺病理结果等

Inclusion criteria

1) Common gynecological diseases: uterine fibroids, uterine sarcoma, endometrial cancer, gestational trophoblastic diseases, cervical cancer, benign and malignant ovarian tumors, endometriosis and other common gynecological diseases. 2) Age 20-80 years old 3) Be able to have surgical or puncture pathological results in our hospital.

排除标准:

1)有重大的疾病,仍需服药控制行为受限的。 2)严重消耗性疾病及严重肝肾功能不全等误纳入的受试者 3)入组后无法完成后续随访或者未在我院手术等 4)肥胖,图像质量差

Exclusion criteria:

1) Those who have a major illness and still need to take medication to control their behavior. 2) Subjects with severe wasting disease and severe liver and kidney insufficiency 3) Unable to complete follow-up after enrollment or not operated on in our hospital 4)Obesity, poor image quality

研究实施时间:

Study execute time:

From 2024-11-30 00:00:00 To 2027-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-11-30 00:00:00 To 2027-08-30 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

550

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

阳性组

样本量:

450

Group:

Positive group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

安徽 

市(区县):

 

Country:

China

Province:

Anhui

City:

单位(医院):

安徽医科大学第一附属医院 

单位级别:

三甲 

Institution
hospital:

the First Affiliated Hospital of Anhui Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

经阴道肿块超声图像

指标类型:

主要指标

Outcome:

transvaginal mass ultrasound images

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

年龄

指标类型:

次要指标

Outcome:

age

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

身体质量指数

指标类型:

次要指标

Outcome:

BMI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

绝经情况

指标类型:

次要指标

Outcome:

menopausal status

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

有无异常阴道出血

指标类型:

次要指标

Outcome:

the presence or absence of abnormal vaginal bleeding

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

癌抗原19-9

指标类型:

次要指标

Outcome:

CA19-9

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

甲胎蛋白

指标类型:

次要指标

Outcome:

AFP

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

人附睾蛋白4

指标类型:

次要指标

Outcome:

HE4

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

D-二聚体

指标类型:

次要指标

Outcome:

D-Dimer

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

糖类抗原125

指标类型:

次要指标

Outcome:

CA125

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 80 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-11-11 10:53:00